1	Clinical and epidemiological characteristics of Coronavirus Disease 2019
2	(COVID-19) patients
3	
4	Shing Cheng Tan
5	
6	UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur,
7	Malaysia
8	
9	Corresponding author:
10	Shing Cheng Tan, PhD
11	Address: UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala
12	Lumpur, Malaysia
13	Email: sctan@ukm.edu.my
14	Tel: +6012-714 7142
15	Fax: +603-9171 7185

16 Summary

17

Background: Numerous groups have reported the clinical and epidemiological characteristics of Coronavirus Disease 2019 (COVID-19) cases; however, the data remained inconsistent. This paper aimed to pool the available data to provide a more complete picture of the characteristics of COVID-19 patients.

22

Methods: A systematic review and pooled analysis was performed. Eligible studies were
 identified from database and hand searches up to March 2, 2020. Data on clinical (including
 laboratory and radiological) and epidemiological (including demographic) characteristics of
 confirmed COVID-19 cases were extracted and combined by simple pooling.

27

28 Results: Of 644 studies identified, 69 studies (involving 48,926 patients) were included in the 29 analysis. The average age of the patients was 49.16 years. A total of 51.46% of the patients 30 were men and 52.32% were non-smokers. Hypertension (50.82%) and diabetes (20.89%) were 31 the most frequent comorbidities observed. The most common symptoms were fever (83.21%), 32 cough (61.74%), and myalgia or fatigue (30.22%). Altered levels of blood and biochemical 33 parameters were observed in a proportion of the patients. Most of the patients (78.50%) had bilateral lung involvements, and 5.86% showed no CT findings indicative of viral pneumonia. 34 Acute respiratory distress syndrome (28.36%), acute cardiac injury (7.89%) and acute kidney 35 36 injury (7.60%) were the most common complications recorded.

37

Conclusions: Clinical and epidemiological characteristics of COVID-19 patients were mostly
 heterogeneous and non-specific. This is the most comprehensive report of the characteristics of
 COVID-19 patients to date. The information presented is important for improving our
 understanding of the spectrum and impact of this novel disease.

42 Introduction

There is an ongoing pandemic of viral pneumonia called Coronavirus Disease 2019 (COVID-19) 43 which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 44 At the time of this writing, the disease has been reported to affect 634,835 people in more than 45 46 200 countries, territories or areas, and cause 29,891 deaths (1). Understanding the clinical and 47 epidemiological characteristics of the disease is important for informing public health decision making, which would enable improvement of surveillance and effective planning of treatment. In 48 January 2020, Huang et al. (2) published the first report on the characteristics of a series of 49 COVID-19 patients in Wuhan, China, the first epicenter of the outbreak. Following that, many 50 51 other groups have reported the clinical and epidemiological features of COVID-19 patients, both 52 in China and in other parts of the world (3-12). However, most of these reports were limited by a 53 small sample size, and the characteristics reported appeared to be inconsistent. For example, in 54 a report involving 99 patients, Chen et al. (3) noted a much higher proportion of men than women, and suggested that men were generally more susceptible to SARS-CoV-2 infection. On 55 56 the other hand, Shi et al. (4) found that the male-to-female ratio among the 81 patients included 57 was close to 1:1, indicating that both genders were equally susceptible to COVID-19. Recently, 58 the World Health Organization (WHO) has declared COVID-19 a global pandemic and the 59 contagion shows no sign of slowing down (13). Thus, it is a timely prompt to obtain a more precise understanding of the disease by combining all available data in the literature. In this 60 study, a systematic review and pooled analysis was performed to characterize the clinical and 61 62 epidemiological features of COVID-19 patients.

63 Methods

64 Search strategy and selection criteria

Three separate searches were performed on PubMed database on March 2, 2020, using the 65 keywords "COVID-19", "2019-nCoV" and "SARS-CoV-2". No language restriction was applied. 66 67 After removal of duplicated records, screening by title and abstract was performed to identify potentially relevant studies. The full-texts of these potentially relevant studies were then 68 evaluated. The reference lists of these studies were also hand-searched to identify additional 69 70 records. Studies were included if they reported any clinical and/or epidemiological data of 71 confirmed COVID-19 patients, regardless of their study design. However, review papers or 72 studies employing secondary analysis of the previously available data were excluded from the analysis. In case of overlapping studies, the ones which the largest sample size or the most 73 74 complete data set were included.

75

76 Data analysis

The following data were extracted from the included studies: name of first author, country, date
of diagnosis, demographic data, smoking status, comorbidities, signs and symptoms,
laboratory/biochemical data, CT findings, and complications of the disease. A simple pooling of
data was performed to provide an overall summary of the clinical and epidemiological
characteristics of the patients. All data are reported as absolute number and/or mean. As
patient-level data were not available in majority of the studies, standard deviation could not be
calculated.

84

85 Role of the funding source

86 There was no funding source for this study. The corresponding author had full access to all the

87 data in the study and had final responsibility for the decision to submit for publication.

88 Results

89 The flowchart of study selection is depicted in Figure 1. A total of 644 records were identified from the PubMed searches. After deduplication, 517 unique records were identified. Following 90 screening by title and abstract, 440 records were removed and full-texts of the remaining 77 91 92 studies were retrieved for assessment of eligibility. Five records were subsequently removed as 93 they reported secondary data or contained insufficient data on clinical and/or epidemiological characteristics of the patients. In addition, three overlapping records were excluded. Eventually, 94 69 studies were included in the current analysis (2-12, 14-71). These 69 studies comprised a 95 96 total of 48,926 confirmed COVID-19 patients, although only appropriate subcohorts were used in the analysis of each clinical/epidemiological characteristic. A great majority of these studies 97 were from mainland China, while five were from Korea and one each from the USA, Germany, 98 99 France, Australia, Italy, Singapore, Vietnam, Nepal, Hong Kong, and Taiwan.

100

The characteristics of the patients are shown in Table 1. The mean age of the patients 101 was 49.16 years. The number of male patients was slightly higher than that of female (51.46% 102 103 vs. 48.54%), and the number of non-smokers was slightly higher than that of smokers (52.32% 104 vs. 47.68%). A minority (25.93%) of the patients had comorbidities, among which hypertension 105 was the most common (50.82%), followed by diabetes (20.89%), cardiovascular and cerebrovascular diseases (16.54%), respiratory system disease (9.70%) and malignancy 106 107 (2.05%). Most of the patients showed at least one sign or symptom at presentation, with only 108 0.8% of the patients were asymptomatic. The most common symptoms seen included fever (83.21%), cough (61.74%), myalgia or fatigue (30.22%), sputum production (20.22%), and 109 dyspnea (16.97%). On average, the length from illness onset to dyspnea was 4.99 days. 110

111

112 The laboratory findings of the patients are also shown in Table 1. Majority (63.06%) of 113 the patients had a normal leukocyte count, but as much as 24.14% and 12.80% respectively

114 showed decreased and increased leukocyte counts. Besides, 51.39% of the patients had a 115 decreased lymphocyte count and 9.63% had a decreased platelet count. Increased levels of 116 aspartate aminotransferase, creatinine, creatine kinase, lactate dehydrogenase, hypersensitive troponin I, procalcitonin and C-reactive protein were observed in 27.45%, 5.19%, 13.25%, 117 118 45.76%, 3.57%, 69.08% and 72.30% of the patients, respectively. 119 120 Analysis of computed tomography (CT) data revealed that most of the patients (78.50%) had bilateral lung involvements, while 15.65% had unilateral lung involvements and 5.86% 121 showed no sign of viral pneumonia. In 41.18% of the patients, all five lung lobes were affected. 122 On the other hand, as much as 17.03%, 11.46%, 12.69% and 17.65% patients respectively had 123 one, two, three and four lobes affected. 124 125 126 It was unknown how many patients had complications following SARS-CoV-2 infection. Nonetheless, among the wide spectrum of complications observed, acute respiratory distress 127

syndrome (ARDS) was most frequently documented (28.36%), followed by acute cardiac injury

129 (7.89%) and acute kidney injury (7.60%).

130 Discussion

131 COVID-19 poses a significant burden on the healthcare system all over the world. A complete 132 understanding of the characteristics of the disease is important for effective surveillance and public health response measures to be implemented in a timely manner. Currently, although we 133 134 have some basic understanding of the clinical and epidemiological features of COVID-19 patients, our knowledge is insufficient. This is because inconsistencies still exist in the findings 135 136 of many published reports, and the sample sizes in most of these reports were too small for a reliable summary to be made. In this work, a systematic review and pooled analysis was 137 138 performed to combine data from 69 previous reports, in order to yield a more accurate summary of the clinical and epidemiological characteristics of COVID-19 patients. 139

140

141 In many instances, susceptibility to viral infections may be related to factors such as 142 gender and smoking habits (72-74). For the former, it is believed that X chromosome inactivation in females may cause cellular mosaicism which ensures the presence of at least 143 one functional copy of X-linked immune genes, thus conferring women an increased resistance 144 145 against viral infections (75). In addition, estrogen, the major female sex hormone, is known to 146 promote adaptive immune response (76), while testosterone, the primary sex hormone in men, 147 could contribute to the suppression of the innate immune response, rendering men more susceptible to viral infections (77, 78). On the other hand, cigarette smoking may reduce the 148 level of circulating immunoglobulins, immune cells, and pro-inflammatory cytokines, as well as 149 150 disrupt the response of antibodies to antigens (72). For these reasons, some studies have suggested that men and smokers are more susceptible to SARS-CoV-2 infections (3, 79). In the 151 present work, we noted that the ratios of male to female and smokers to non-smokers were 152 153 close to 1:1. Although the relative risk or odds ratio of the association between these variables 154 and SARS-CoV-2 infection could not be computed due to the lack of a comparison group, a proportion of approximately 1:1 suggests that susceptibility to SARS-CoV-2 infection is universal. 155

156

The present work also showed that the symptoms of COVID-19 were generally non-157 158 specific, thus the disease cannot be reliably distinguished from other infectious diseases based on the symptoms alone. The most commonly observed symptoms were similar to those of the 159 previous coronavirus disease outbreaks (MERS and SARS), i.e. fever, cough, and myalgia or 160 161 fatigue. Nevertheless, compared to MERS and SARS, the proportion of afebrile patients was 162 much higher in COVID-19 (16.79% cf. 2% in MERS and 0-1% in SARS) (80). This indicates that a significant number of COVID-19 patients would be missed if surveillance and monitoring 163 164 systems focus largely on temperature screening, as commonly practiced in airports (81, 82). The present work also showed that dyspnea was observed in only 16.97% of the patients. This 165 contradicts with advisories and guidelines published by many health authorities, which suggest 166 167 that dyspnea is a commonly observed symptom in COVID-19 (83-89). Besides, it was observed 168 that 0.80% of the patients were asymptomatic. Currently, whether asymptomatic patients can transmit the virus to other individuals is not fully known, but it is highly possible (35). Thus, 169 170 although the number of asymptomatic patients was low, identifying and isolating such patients 171 to prevent uncontrolled disease spread would prove very challenging. It is therefore important 172 for diagnostic tests to be performed on asymptomatic medium- and high-risk individuals to facilitate early detection and prevention of SARS-CoV-2 transmission. In addition to nucleic acid 173 testing using real-time reverse transcription polymerase chain reaction, some studies have 174 175 suggested the potential usability of chest CT for COVID-19 diagnosis (90, 91). However, in the 176 present work, we found that 5.86% of the patients did not have abnormalities on CT scans. Thus, 177 although CT findings have substantial accuracy in identifying the disease (90, 91), the results need 178 to be interpreted with caution.

179

SARS-CoV-2 is known to infect a cell by first binding to its angiotensin converting
 enzyme 2 (ACE2) receptor (92). Apart from the lung, high expression of ACE2 receptor is also

182 observed in several other organs such as the heart, kidney, and intestine, as well as the in 183 lymphocytes (93, 94). Several previous studies reported that a decreased lymphocyte count was a common feature of SARS-CoV-2 infection (2, 3, 7, 30, 41). In the present work, 184 lymphopenia was observed in 51.39% of the patients. A decreased lymphocyte count implies a 185 186 weakening adaptive immune system. Considering the high expression of ACE2 in lymphocytes, 187 it has been postulated that SARS-CoV-2 may directly infect and attack lymphocytes, thus impairing the immune system (95). Besides the decrease in lymphocyte count, the present 188 189 study also showed that many COVID-19 patients had increased levels of C-reactive protein, 190 creatine kinase, lactate dehydrogenase and procalcitonin. High levels of C-reactive protein and creatine kinase suggest that sustained inflammatory response occurs following SARS-CoV-2 191 infection, whereas high levels of lactate dehydrogenase and procalcitonin indicate the virus 192 193 could, either directly or indirectly, cause tissue injury. A previous work reported that a low 194 lymphocyte count and high levels of lactate dehydrogenase and C-reactive protein were among the parameters found to be correlated with severity of lung injury in COVID-19 patients, as 195 measured using the Murray scores (17). Nonetheless, the relationship between these variables 196 197 and severity of COVID-19 was not investigated in the present work due to the insufficient data 198 available.

199

A few limitations exist in the present work. First, there were instances where a same 200 201 patient was described in multiple reports (15, 96). Efforts have been made to identify such 202 patients by meticulously reviewing the descriptions of the patients in each report. However, since all patients were anonymized, it was challenging to identify all overlapping patients. Thus, 203 204 there is a possibility that some overlapping patients were not removed from our analysis and 205 their characteristics were overreported. Besides, since patient-level data were not reported in 206 most of the studies, median values and standard deviations, which understandably provide 207 more meaningful information, could not be computed. Finally, as mentioned above, various

- 208 comparisons among the patients (e.g. severe vs. mild, and death vs. survivor) could not be209 analyzed due to insufficient data available.
- 210

211 Conclusion

- In conclusion, this report has successfully provided a more complete picture of the clinical and
- 213 epidemiological characteristics of COVID-19 patients. A wide variation exists in the clinical
- 214 manifestation of the disease. As the outbreak continues to escalate and SARS-CoV-2 continues
- to mutate (97), it is important to consistently update the characteristics of the patients in order to
- 216 monitor whether evolving strains of the virus could cause the disease differently. Sharing of
- 217 clinical and epidemiological data among the scientific community is highly important for
- informing public health decision making for controlling the spread of the disease.

219 Contributor

220 SCT contributed solely to this work.

221

- 222 Declaration of interests
- 223 The author declares no competing interests.

224

225 Acknowledgments

226 No funding was obtained for this work.

227 References

- World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 69.
 2020.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England).
 2020;395(10223):497-506.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395(10223):507-13.
- 4. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81
 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet
 Infectious diseases. 2020.
- Albarello F, Pianura E, Di Stefano F, Cristofaro M, Petrone A, Marchioni L, et al. 2019novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020.
- Ki M, nCo VT. Epidemiologic characteristics of early cases with 2019 novel coronavirus
 (2019-nCoV) disease in Republic of Korea. Epidemiology and health. 2020:e2020007.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
 China. Jama. 2020.
- Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First
 cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations
 and control measures, January 2020. Euro surveillance : bulletin Europeen sur les
 maladies transmissibles = European communicable disease bulletin. 2020;25(6).
- 252 9. COVID-19 National Incident Room Surveillance Team. COVID-19, Australia:
 253 Epidemiology Report 4 (Reporting week ending 19:00 AEDT 22 February 2020).
 254 Communicable diseases intelligence (2018). 2020;44.
- Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese medical journal. 2020.
- Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19
 infection in Beijing. The Journal of infection. 2020.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically
 ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
 retrospective, observational study. The Lancet Respiratory medicine. 2020.
- World Health Organization. WHO Director-General's opening remarks at the media
 briefing on COVID-19 11 March 2020 2020. Available from:
 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the media-briefing-on-covid-19---11-march-2020.
- 14. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic
 procedure for four cases with 2019 novel coronavirus pneumonia receiving combined
 Chinese and Western medicine treatment. Bioscience trends. 2020.
- 15. Kim JY, Choe PG. The First Case of 2019 Novel Coronavirus Pneumonia Imported into
 Korea from Wuhan, China: Implication for Infection Prevention and Control Measures.
 2020;35(5):e61.
- 16. Lim J, Jeon S. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-
- 19 Infected Pneumonia Monitored by Quantitative RT-PCR. 2020;35(6):e79.

	. –	
275	17.	Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical
276		indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science
277	4.0	China Life sciences. 2020.
278	18.	Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al.
279		Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.
280		Radiology. 2020.
281	19.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
282		Patients with Pneumonia in China, 2019. The New England journal of medicine.
283		2020;382(8):727-33.
284	20.	Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of
285		2019 Novel Coronavirus in the United States. The New England journal of medicine.
286		2020.
287	21.	Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
288		Wuhan, China, of Novel Coronavirus-Infected Pneumonia. 2020.
289	22.	Chinese National Health Commission. [Briefing on the pneumonia epidemic situation, 23
290		January 2020] 2020. Available from:
291		http://www.nhc.gov.cn/yjb/s3578/202001/5d19a4f6d3154b9fae328918ed2e3c8a.shtml.
292	23.	Chung M, Bernheim A. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV).
293		2020:200230.
294	24.	Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV)
295		Pneumonia. 2020:200236.
296	25.	Shi H, Han X. Evolution of CT Manifestations in a Patient Recovered from 2019 Novel
297		Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. 2020:200269.
298	26.	Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging Coronavirus 2019-nCoV
299		Pneumonia. 2020:200274.
300	27.	Fang Y, Zhang H. CT Manifestations of Two Cases of 2019 Novel Coronavirus (2019-
301		nCoV) Pneumonia. 2020:200280.
302	28.	Duan YN, Qin J. Pre- and Posttreatment Chest CT Findings: 2019 Novel Coronavirus
303		(2019-nCoV) Pneumonia. 2020:200323.
304	29.	Xie X. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR
305		Testing. Radiology. 2020:200343.
306	30.	Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of
307		140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020.
308	31.	Chen L, Liu W, Zhang Q. RNA based mNGS approach identifies a novel human
309		coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.
310		2020;9(1):313-9.
311	32.	Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the
312		2019 novel coronavirus indicating potential person-to-person transmission during the
313		incubation period. The Journal of infectious diseases. 2020.
314	33.	Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, et al. Initial CT findings and
315		temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a
316		study of 63 patients in Wuhan, China. Journal of medical virology. 2020.
317	34.	Lin X. Novel Coronavirus Pneumonia Outbreak in 2019: Computed Tomographic
318	<u> </u>	Findings in Two Cases. Journal of Korean medical science. 2020;21(3):365-8.
319	35.	Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier
320		Transmission of COVID-19. Jama. 2020.
321	36.	Kim JY, Ko JH. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in
322	~-	Korea. 2020;35(7):e86.
323	37.	Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. [Preliminary study of the
324		relationship between novel coronavirus pneumonia and liver function damage: a

325		multicenter study]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =
326		Chinese journal of hepatology. 2020;28(2):148-52.
327	38.	Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of
328		patients with 2019 novel coronavirus SARS-CoV-2. European journal of nuclear
329		medicine and molecular imaging. 2020.
330	39.	Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019-nCoV viral RNA in
331		blood is a strong indicator for the further clinical severity. Emerging microbes &
332		infections. 2020;9(1):469-73.
333	40.	Pan F, Ye T. Time Course of Lung Changes On Chest CT During Recovery From 2019
334		Novel Coronavirus (COVID-19) Pneumonia. 2020:200370.
335	41.	Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of 29
336		patients with 2019 novel coronavirus pneumonia]. Zhonghua jie he he hu xi za zhi =
337		Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
338		2020;43(0):E005.
339	42.	Ai T, Yang Z. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease
340		2019 (COVID-19) in China: A Report of 1014 Cases. 2020:200642.
341	43.	Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A Locally Transmitted Case of SARS-
342		CoV-2 Infection in Taiwan. 2020.
343	44.	Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in
344		Upper Respiratory Specimens of Infected Patients. The New England journal of
345		medicine. 2020.
346	45.	Feng K, Yun YX, Wang XF, Yang GD, Zheng YJ, Lin CM, et al. [Analysis of CT features
347		of 15 Children with 2019 novel coronavirus infection]. Zhonghua er ke za zhi = Chinese
348		journal of pediatrics. 2020;58(0):E007.
349	46.	Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis
350		and treatment of a case infected with coronavirus disease 2019. Journal of medical
351		virology. 2020.
352	47.	Fang X, Zhao M, Li S, Yang L, Wu B. Changes of CT Findings in a 2019 Novel
353		Coronavirus (2019-nCoV) pneumonia patient. QJM : monthly journal of the Association
354		of Physicians. 2020.
355	48.	Gou SM, Yin T, Xiong JX, Peng T, Li Y, Wu HS. [Treatment of pancreatic diseases and
356		prevention of infection during outbreak of 2019 coronavirus disease]. Zhonghua wai ke
357		za zhi [Chinese journal of surgery]. 2020;58(0):E006.
358	49.	Li YY, Wang WN, Lei Y, Zhang B, Yang J, Hu JW, et al. [Comparison of the clinical
359		characteristics between RNA positive and negative patients clinically diagnosed with
360		2019 novel coronavirus pneumonia]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe
361		he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
362		2020;43(0):E023.
363	50.	Wang J, Liu J, Wang Y, Liu W, Chen X, Sun C, et al. [Dynamic changes of chest CT
364	00.	imaging in patients with corona virus disease-19 (COVID-19)]. Zhejiang da xue xue bao
365		Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(1):0.
366	51.	Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in Patients with
367	01.	Corona Virus Disease 2019 and its Relationship with Clinical Features. Investigative
368		radiology. 2020.
369	52.	Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al. Potential Presymptomatic
370	52.	Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerging infectious
370 371		diseases. 2020;26(5).
372	53.	Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest Radiographic and CT
372	55.	Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients
373 374		Treated in Korea. Korean journal of radiology. 2020.
5/4		Treated in Norea. Norean journal of radiology. 2020.

375 54. Wei J. 2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings. Infection & chemotherapy. 2020. 376 Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of 377 55. 378 patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, 379 China: retrospective case series, 2020:368:m606. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The 380 56. epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases 381 382 (COVID-19) in China]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue 383 zazhi. 2020;41(2):145-51. Kam KQ, Yung CF, Cui L, Lin Tzer Pin R, Mak TM, Maiwald M, et al. A Well Infant with 57. 384 Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clinical infectious 385 386 diseases : an official publication of the Infectious Diseases Society of America. 2020. 387 58. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clinical 388 infectious diseases : an official publication of the Infectious Diseases Society of America. 389 390 2020. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-391 59. 392 19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine. 2020. 393 394 60. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020. 395 Van Cuong L, Giang HTN, Linh LK, Shah J, Van Sy L, Hung TH, et al. The first 396 61. 397 Vietnamese case of COVID-19 acquired from China. The Lancet Infectious diseases. 398 2020. 399 62. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster 400 with SARS-CoV-2 infection. The Lancet Infectious diseases. 2020. Bernheim A, Mei X. Chest CT Findings in Coronavirus Disease-19 (COVID-19): 401 63. 402 Relationship to Duration of Infection. 2020:200463. Shrestha R, Shrestha S, Khanal P, Bhuvan KC. Nepal's First Case of COVID-19 and 403 64. public health response. Journal of medical virology. 2020. 404 65. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival 405 secretions of patients with SARS-CoV-2 infection. 2020. 406 Qin C, Liu F, Yen TC, Lan X. (18)F-FDG PET/CT findings of COVID-19: a series of four 407 66. highly suspected cases. Journal of medical virology. 2020. 408 Kwok KO, Wong V, Wei VWI, Wong SYS, Tang JW. Novel coronavirus (2019-nCoV) 409 67. 410 cases in Hong Kong and implications for further spread. The Journal of infection. 2020. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and 411 68. imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-412 center study in Wenzhou city, Zhejiang, China. The Journal of infection. 2020. 413 Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and computed 414 69. tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2. 415 416 The Journal of infection. 2020. 70. Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, et al. 2019 novel coronavirus 417 418 disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020. 419 71. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of 420 421 Coronavirus Disease 2019 in China. The New England journal of medicine. 2020. 72. Arcavi L, Benowitz NL. Cigarette smoking and infection. Archives of internal medicine. 422 423 2004;164(20):2206-16. 73. Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the 424 occurrence of influenza - Systematic review. The Journal of infection. 2019;79(5):401-6. 425

426	74.	Klein SL, Flanagan KL. Sex differences in immune responses. Nature reviews
427	75	Immunology. 2016;16(10):626-38.
428	75.	Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Moller M. The X chromosome and
429	76	sex-specific effects in infectious disease susceptibility. Human genomics. 2019;13(1):2.
430	76.	Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL. 17beta-estradiol protects females
431		against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell
432 433	77.	responses in the lungs. Journal of virology. 2014;88(9):4711-20. Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression
433 434	11.	in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity.
434 435		Biology of reproduction. 2008;78(3):432-7.
435 436	78.	Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of
430 437	70.	testosterone replacement on endogenous inflammatory cytokines and lipid profiles in
437		hypogonadal men. The Journal of clinical endocrinology and metabolism.
438		2004;89(7):3313-8.
440	79.	Cai G. Tobacco-use disparity in gene expression of ACE2, the receptor of 2019-nCov.
441	75.	Preprints. 2020:2020020051.
442	80.	Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet (London,
443	001	England). 2015;386(9997):995-1007.
444	81.	Quilty BJ, Clifford S, Flasche S, Eggo RM. Effectiveness of airport screening at detecting
445		travellers infected with novel coronavirus (2019-nCoV). Euro surveillance : bulletin
446		Europeen sur les maladies transmissibles = European communicable disease bulletin.
447		2020;25(5).
448	82.	Bwire GM, Paulo LS. Coronavirus disease-2019: is fever an adequate screening for the
449		returning travelers? Tropical medicine and health. 2020;48:14.
450	83.	Victoria State Government. 2019 Coronavirus disease (COVID-19) 2020. Available from:
451		https://www2.health.vic.gov.au/about/news-and-events/healthalerts/2019-Coronavirus-
452		diseaseCOVID-19.
453	84.	Government of New York City. COVID-19: Symptoms, Chronic Health Risks 2020.
454		Available from: https://www1.nyc.gov/site/doh/covid/covid-19-symptoms-chronic-health-
455		risks.page.
456	85.	King County Government. Public Health: What to do if you have confirmed or suspected
457		COVID-19 or are worried that you may have COVID-19 2020. Available from:
458		https://www.kingcounty.gov/depts/health/news/2020/March/5-suspected-covid.aspx.
459	86.	Washington State Department of Health. What to do if you have confirmed or suspected
460		coronavirus disease (COVID-19) 2020. Available from:
461	07	https://www.doh.wa.gov/Portals/1/Documents/1600/coronavirus/COVIDcasepositive.pdf.
462	87.	Ministry of Foreign Affairs and Trade (New Zealand). COVID-19 (Coronavirus) 2020.
463	00	Available from: https://safetravel.govt.nz/covid-19-coronavirus.
464	88.	Government of Telangana Department of Health and Family Welfare (India). Corona
465	00	Virus 2020. Available from: <u>http://124.124.103.93/COVID/home.htm</u> .
466	89.	Saudi Center for Disease Prevention and Control, Ministry of Health (Saudi Arabia).
467		Coronavirus Disease 19 (COVID-19) Guidelines 2020. Available from: https://www.moh.gov.sa/CCC/healthp/regulations/Documents/Coronavirus%20Disease
468 469		%202019%20Guidelines%20v1.1pdf.
469 470	90.	Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and
470 471	30.	Management. AJR American journal of roentgenology. 2020:1-7.
471	91.	Wang K, Kang S, Tian R, Zhang X, Zhang X, Wang Y. Imaging manifestations and
472	51.	diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan
474		area. Clinical radiology. 2020.
17 T		aroar omnoarradiology. LoLor

- 475 92. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al.
- 476 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
 477 Proven Protease Inhibitor. Cell. 2020.
- 478 93. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor
 479 of 2019-nCoV on the epithelial cells of oral mucosa.
- 480 94. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the
 481 receptor ACE2 expression reveals the potential risk of different human organs
 482 vulnerable to 2019-nCoV infection. Frontiers of medicine. 2020.
- 483 95. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts
 484 disease severity of COVID-19: a descriptive and predictive study.
- 485 96. Kim JY. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea.
 486 Journal of Korean medical science. 2020;35(7):e86.
- Phan T. Genetic diversity and evolution of SARS-CoV-2. Infection, genetics and
 evolution : journal of molecular epidemiology and evolutionary genetics in infectious
 diseases. 2020;81:104260.
- 490

491

492 Table 1: Characteristics of COVID-19 patients


Characteristics	Number of patients analyzed	Number/Mean
Age (years)	1,725	49.16
Sex	44,760	
Male	, -	23,032 (51.46%)
Female		21,728 (48.54%)
Smoking status	2,030	21,120 (1010170)
Smokers	2,000	968 (47.68%)
Non-smokers		1,062 (52.32%)
Comorbidities	21,020	1,002 (02.0270)
Yes	21,020	E 151 (25 020/)
No		5,451 (25.93%)
	F 4F0	15,569 (74.07%)
Type of comorbidities	5,450	
Hypertension		2,683 (50.82%)
Diabetes		1,103 (20.89%)
Cardiovascular and cerebrovascular diseases		873 (16.54%)
Respiratory system disease		512 (9.70%)
Malignancy		108 (2.05%)
Presence of symptoms	3,117	
Yes		3092 (99.20%)
No		25 (0.80%)
Signs and symptoms		
Fever	3,097	2577 (83.21%)
Cough	3,097	1912 (61.74%)
Myalgia or fatigue	3,117	942 (30.22%)
Sputum production	3,115	630 (20.22%)
• •	3,093	525 (16.97%)
Dyspnea	179	· · ·
Length from illness onset to dyspnea (days)		4.99
Headache	3,114	325 (10.44%)
Sore throat	3,117	250 (8.02%)
Chill	3,117	201 (6.45%)
Nausea and vomiting	3,116	142 (4.56%)
Diarrhea	3,113	136 (4.37%)
Chest tightness but not pain	3,117	94 (3.02%)
Nasal congestion or runny nose	3,117	64 (2.05%)
Loss of appetite	3,116	62 (1.99%)
Abdominal pain	3,116	38 (1.22%)
Rhinorrhoea	3,117	35 (1.12%)
Pharyngalgia	3,117	33 (1.06%)
Dizziness	3,117	32 (1.03%)
Chest pain	3,117	25 (0.80%)
Hemoptysis	3,115	23 (0.74%)
Respiratory rate >24 breaths per min	3,117	22 (0.71%)
Malaise		. ,
	3,117	21 (0.67%)
Heart palpitation	3,117	14 (0.45%)
Conjunctivitis	3,117	10 (0.32%)
Confusion	3,117	10 (0.32%)
Blood in sputum	3,117	3 (0.10%)
Anthralgia	3,117	2 (0.06%)

Gastrointestinal reaction	3,117	1 (0.03%)
Back pain	3,117	1 (0.03%)
Constipation	3,117	1 (0.03%)
Skin tingling	3,117	1 (0.03%)
Somnolence	3,117	1 (0.03%)
Sneezing	3,117	1 (0.03%)
Jaundice	3,117	1 (0.03%)
Respiratory symptoms*	3,117	7 (0.22%)
Laboratory findings		
Leukocyte count (× 10 ⁹ per L)	801	5.60
Decreased	961	232 (24.14%)
Normal	961	606 (63.06%)
Increased	961	123 (12.80%)
Neutrophil count (× 10 ⁹ per L)	571	3.63
Lymphocyte count (× 10 ⁹ per L)	849	0.97
Decreased	827	425 (51.39%)
Normal	827	402 (48.61%)
Hemoglobin, g/L	336	127.47
Platelet count, (10º per L)	635	181.58
Decreased	561	54 (9.63%)
Prothrombin time (s)	562	11.94
Activated partial thromboplastin time (s)	360	29.96
D-dimer (mg/L)	726	1.13
D-dimer (mg/L) when one study was removed [†]	645	0.45
Albumin (g/L)	473	36.84
Alanine aminotransferase (U/L)	634	31.55
Aspartate aminotransferase (U/L)	614	32.59
Normal	499	362 (72.55%)
Increased	499	137 (27.45%)
Total bilirubin (mmol/L)	659	12.04
Potassium (mmol/L)	44	4.23
Sodium (mmol/L)	44	138.48
Creatinine (µmol/L)	633	72.45
Normal	231	219 (94.81%)
Increased	231	12 (5.19%)
Creatine kinase (U/L)	636	93.66
Normal	400	347 (86.75%)
Increased	400	. ,
	400 547	53 (13.25%) 261.44
Lactate dehydrogenase (U/L)		
Normal	413	224 (54.24%)
	413	189 (45.76%)
Hypersensitive troponin I (pg/mL)	179	5.91
>28 (99th percentile)	28	1 (3.57%)
Procalcitonin (ng/mL)	334	0.21
Normal	359	111 (30.92%)
Increased	359	248 (69.08%)
Increased C-reactive protein	870	629 (72.30%)
CT findings		
Lung involvement	1,144	
Bilateral		898 (78.50%)
Unilateral		179 (15.65%)

No abnormalities		67 (5.86%)
Number of lobes affected	323	
1		55 (17.03%)
2		37 (11.46%)
3		41 (12.69%)
4		57 (17.65%)
5		133 (41.18%)
Complications	342	
Acute respiratory distress syndrome		97 (28.36%)
Acute cardiac injury		27 (7.89%)
Acute kidney injury		26 (7.60%)
Arrhythmia		23 (6.73%)
Shock		20 (5.85%)
Hyperglycemia		18 (5.26%)
Hepatic insufficiency / liver dysfunction		17 (4.97%)
Acute respiratory injury		8 (2.34%)
Hospital acquired/Ventilator associated		0 (0 0 40/)
pneumonia		8 (2.34%)
RNAaemia		6 (1.75%)
Secondary infection		4 (1.17%)
Renal insufficiency		2 (0.58%)
Gastrointestinal hemorrhage		2 (0.58%)
Cardiac failure		1 (0.29%)
Pneumothorax		1 (0.29%)
Urinary tract infection		1 (0.29%)
Bacteremia		1 (0.29%)
* Respiratory symptoms included multiple symptoms su	ich as cough an	d sore throat, but they

were not reported separately in the original publications Data from Shi et al. (4) was removed as the value reported was an outlier t

493



494

495 Figure 1: Flow chart of study selection